Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application

European Journal of Pharmacology

Volumn 532, Issue 1-2, 2006, Pages 128-137

  Harada, Daisuke ^a   Tsukumo, Yukihito ^a   Takashima, Yuko ^a   Manabe, Haruhiko ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

2,4,6 trinitro 1 chlorobenzene; Dermatitis; Phosphodiesterase 4; Rolipram

Indexed keywords

CYCLOSPORIN A; CYTOKINE; IMMUNOGLOBULIN E; INTERLEUKIN 4; PHOSPHODIESTERASE IV INHIBITOR; PICRYL CHLORIDE; PREDNISOLONE; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CERVICAL LYMPH NODE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EAR; ENZYME ACTIVITY; IMMUNOGLOBULIN BLOOD LEVEL; LYMPH NODE CELL; LYMPHOCYTE COUNT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL COUNT; CYCLOSPORINE; CYTOKINES; DERMATITIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EAR, INNER; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; LYMPH NODES; MALE; MICE; MICE, INBRED BALB C; PEROXIDASE; PHOSPHODIESTERASE INHIBITORS; PICRYL CHLORIDE; PREDNISOLONE; ROLIPRAM; T-LYMPHOCYTES; TIME FACTORS; WEIGHT GAIN;

EID: 33644510427     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.12.005     Document Type: Article

References (49)

1. M. Akdis, C.A. Akdis, L. Weigl, R. Disch, and K. Blaser Skin-homing, CLA+ memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counter-regulation by CLA-memory T cells J. Immunol. 159 1997 4611 4619
2. M.E. Ballestas, and E.N. Benveniste Elevation of cyclic AMP levels in astrocytes antagonizes cytokine-induced adhesion molecule expression J. Neurochem. 69 1997 1438 1448
3. W. Bäumer, G. Gorr, J. Hoppmann, A.M. Ehinger, B. Ehinger, and M. Kietzmann Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis Eur. J. Pharmacol. 446 2002 195 200
4. K. Blease, A. Burke-Gaffney, and P.G. Hellewell Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4 Br. J. Pharmacol. 124 1998 229 237
5. J.D. Bos, M.L. Kapsenberg, and J.H. Smitt Pathogenesis of atopic eczema Lancet 343 1994 1338 1341
6. P.P. Bradley, D.A. Priebat, R.D. Christensen, and G. Rothstein Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker J. Invest. Dermatol. 78 1982 206 209
7. J.M. Butler, S.C. Chan, S. Stevens, and J.M. Hanifin Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis J. Allergy Clin. Immunol. 71 1983 490 497
8. C.S. Chujor, F. Hammerschmid, and C. Lam Cyclic nucleotide phosphodiesterase 4 subtypes are differentially expressed by primary keratinocytes and human epidermoid cell lines J. Invest. Dermatol. 110 1998 287 291
9. K.D. Cooper, K. Kang, S.C. Chan, and J.M. Hanifin Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro J. Invest. Dermatol. 84 1985 477 482
10. I.C. Crocker, R.G. Townley, and M.M. Khan Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells Immunopharmacology 31 1996 223 235
11. G. Dent, M.A. Giembycz, P.M. Evans, K.F. Rabe, and P.J. Barnes Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol J. Pharmacol. Exp. Ther. 271 1994 1167 1174
12. A.M. Ehinger, G. Gorr, J. Hoppmann, E. Telser, B. Ehinger, and M. Kietzmann Effects of the phosphodiesterase 4 inhibitor RPR 73401 in a model of immunological inflammation Eur. J. Pharmacol. 392 2000 93 99
13. A. Elbe-Burger, A. Egyed, S. Olt, R. Klubal, U. Mann, K. Rappersberger, A. Rot, and G. Stingl Overexpression of IL-4 alters the homeostasis in the skin J. Invest. Dermatol. 118 2002 767 778
14. D.M. Essayan, A. Kagey-Sobotka, L.M. Lichtenstein, and S.K. Huang Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors J. Pharmacol. Exp. Ther. 282 1997 505 512
15. Y. Fujii, H. Takeuchi, K. Tanaka, S. Sakuma, Y. Ohkubo, and S. Mutoh Effects of FK506 (tacrolimus hydrate) on chronic oxazolone-induced dermatitis in rats Eur. J. Pharmacol. 456 2002 115 121
16. F. Gantner, R. Kupferschmidt, C. Schudt, A. Wendel, and A. Hatzelmann In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors Br. J. Pharmacol. 121 1997 221 231
17. M.A. Giembycz Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 59 2000 193 212
18. S.R. Grewe, S.C. Chan, and J.M. Hanifin Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness J. Allergy Clin. Immunol. 70 1982 452 457
19. C.E. Griffiths, E.J. Van Leent, M. Gilbert, and J. Traulsen Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis Br. J. Dermatol. 147 2002 299 307
20. D.E. Griswold, E.F. Webb, A.M. Badger, P.D. Gorycki, P.A. Levandoski, M.A. Barnette, M. Grous, S. Christensen, and T.J. Torphy SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo J. Pharmacol. Exp. Ther. 287 1998 705 711
21. J.M. Hanifin, and S.C. Chan Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis J. Invest. Dermatol. 105 1995 84S 88S
22. J.M. Hanifin, S.C. Chan, J.B. Cheng, S.J. Tofte, W.R. Henderson Jr., D.S. Kirby, and E.S. Weiner Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis J. Invest. Dermatol. 107 1996 51 56
23. J.M. Hanifin, and S. Chan Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies J. Am. Acad. Dermatol. 41 1999 72 77
24. D. Harada, C. Takada, Y. Tsukumo, K. Takaba, and H. Manabe Analyses of a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application J. Dermatol. Sci. 37 2005 159 167
25. S. Hiratsuka, A. Yoshida, C. Ishioka, and H. Kimata Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis J. Allergy Clin. Immunol. 98 1996 107 113
26. Y. Inoue, M. Isobe, T. Shiohara, Y. Goto, and H. Hayashi Protective and curative effects of topically applied CX-659S, a novel diaminouracil derivative, on chronic picryl chloride-induced contact hypersensitivity responses Br. J. Dermatol. 147 2002 675 682
27. Y. Inoue, M. Isobe, T. Shiohara, and H. Hayashi Inhibitory activity of CX-659S, a novel diaminouracil derivative, against the rebound phenomenon following withdrawal of corticosteroid therapy for chronic contact hypersensitivity responses Int. Arch. Allergy Immunol. 131 2003 143 152
28. A. Kapp The role of eosinophilic granulocytes for the pathogenesis of atopic dermatitis/neurodermatitis, Eosinophilic products as markers of disease activity Hautarzt 44 1993 432 436
29. T. Kawakami, Y. Soma, E. Morita, O. Koro, S. Yamamoto, K. Nakamura, K. Tamaki, K. Yajima, A. Imaizumi, R. Matsunaga, N. Murakami, M. Kashima, and M. Mizoguchi Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation Dermatology 203 2001 32 37
30. Y. Kawase, T. Hoshino, K. Yokota, A. Kuzuhara, Y. Kirii, E. Nishiwaki, Y. Maeda, J. Takeda, M. Okamoto, S. Kato, T. Imaizumi, H. Aizawa, and K. Yoshino Exacerbated and prolonged allergic and non-allergic inflammatory cutaneous reaction in mice with targeted interleukin-18 expression in the skin J. Invest. Dermatol. 121 2003 502 509
31. H. Kimata Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate Ann. Allergy Asthma Immunol. 82 1995 293 295
32. H. Kitagaki, N. Ono, K. Hayakawa, T. Kitazawa, K. Watanabe, and T. Shiohara Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile J. Immunol. 159 1997 2484 2491
33. T. Kitajima, K. Ariizumi, M. Mohamadazadeh, D. Edelbaum, P.R. Bergstresser, and A. Takashima T cell-dependent secretion of IL-1 beta by a dendritic cell line (XS52) derived from murine epidermis J. Immunol. 155 1995 3794 3800
34. L. Kristal, and P.A. Klein Atopic dermatitis in infants and children, an update Pediatr. Clin. North Am. 47 2000 877 895
35. D.Y. Leung, L.A. Diaz, V. DeLeo, and N.A. Soter Allergic and immunologic skin disorders JAMA 278 1997 1914 1923
36. C.D. Manning, M. Burman, S.B. Christensen, L.B. Cieslinski, D.M. Essayan, and M. Grous Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B Br. J. Pharmacol. 128 1999 1393 1398
37. J.M. Naeyaert, J.M. Lachapelle, H. Degreef, M. de la Brassinne, M. Heenen, and J. Lambert Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus Dermatology 198 1999 145 152
38. H. Nagai, H. Hiyama, A. Matsuo, Y. Ueda, N. Inagaki, and K. Kawada FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice J. Pharmacol. Exp. Ther. 283 1997 321 327
39. T. Nakada, K. Watanabe, T. Matsumoto, K. Santa, K. Triizuka, and T. Hanawa Effect of orally administered Hochu-ekki-to, a Japanese herbal medicine, on contact hypersensitivity caused by repeated application of antigen Int. Immunopharmacol. 2 2002 901 911
40. M.J. Safko, S.C. Chan, K.D. Cooper, and J.M. Hanifin Heterologous desensitization of leukocytes: a possible mechanism of beta adrenergic blockade in atopic dermatitis J. Allergy Clin. Immunol. 68 1981 218 225
41. A. Saitoh, N. Yasaka, A. Osada, K. Nakamura, M. Furue, and K. Tamaki Migration of Langerhans cells in an in vitro organ culture system: IL-6 and TNF-alpha are partially responsible for migration into the epidermis J. Dermatol. Sci. 19 1999 166 174
42. L.F. Santamaria, J.M. Palacios, and J. Beleta Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram Br. J. Pharmacol. 121 1997 1150 1154
43. T. Schneider, and A.C. Issekutz Quantitation of eosinophil and neutrophil infiltration into rat lung by specific assays for eosinophil peroxidase and myeloperoxidase, Application in a Brown Norway rat model of allergic pulmonary inflammation J. Immunol. Methods 198 1996 1 14
44. D. Schoeler, A. Grutzkau, B.M. Henz, J. Kuchler, and S. Kruger-Krasagakis Interleukin-6 enhances whereas tumor necrosis factor alpha and interferons inhibit integrin expression and adhesion of human mast cells to extracellular matrix proteins J. Invest. Dermatol. 120 2003 795 801
45. Y. Shimada, M. Hasegawa, Y. Kaburagi, Y. Hamaguchi, K. Komura, E. Saito, K. Takehara, D.A. Steeber, T.F. Tedder, and S. Sato l-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity J. Immunol. 170 2003 4325 4334
46. R. Sidbury, and J.M. Hanifin Systemic therapy of atopic dermatitis Clin. Exp. Dermatol. 25 2000 559 566
47. J.M. Sowden, J. Berth-Jones, J.S. Ross, R.J. Motley, R. Marks, A.Y. Finlay, M.S. Salek, R.A. Graham-Brown, B.R. Allen, and R.D. Camp Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis Lancet 338 1991 137 140
48. M.M. Teixeira, R.W. Gristwood, N. Cooper, and P.G. Hellewell Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. 18 1997 164 171
49. T. van Joost, F. Heule, M. Korstanje, M.J. van den Broek, H.J. Stenveld, and W.A. van Vloten Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study Br. J. Dermatol. 130 1994 634 640